Return to homepagePandemic Pact

Development of hACE2-Fc fusion protein for therapy purposes

  • Funded by Ministry for Innovation and Technology (Hungary)
  • Total publications:0 publications
Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    Ministry for Innovation and Technology (Hungary)

  • Research Location

    Hungary

  • Lead Research Institution

    Eötvös Loránd University, University of Pécs, Gedeon Richter Plc., ImmunoGenes Kft.

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

A consortium has been set up to develop a therapeutic agent to combat the coronavirus with the involvement of university, research institute and private sector participants. With the involvement of the members of the consortium, Hungarian pharmaceutical company Richter Gedeon is producing a fusion protein (hACE2-Fc) that neutralises and destroys cells that have been infected with the virus within the patient's body.